Akebia Therapeutics Inc’s filing revealed that its CEO and President Butler John P. unloaded Company’s shares for reported $84928.0 on Mar 03 ’25. In the deal valued at $1.83 per share,46,409 shares were sold. As a result of this transaction, Butler John P. now holds 2,557,921 shares worth roughly $6.14 million.
Then, Burke Steven Keith sold 7,144 shares, generating $13,074 in total proceeds. Upon selling the shares at $1.83, the SVP, Chief Medical Officer now owns 809,090 shares.
Before that, Burke Steven Keith bought 7,144 shares. Akebia Therapeutics Inc shares valued at $13,086 were divested by the Officer at a price of $1.83 per share.
A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in late August from “a Neutral” to “a Buy”. Piper Sandler also remained covering AKBA and has increased its forecast on May 31, 2023 with a “an Overweight” recommendation from previously “Neutral” rating. Piper Sandler revised its rating on March 31, 2022. It rated AKBA as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of AKBA
On Monday, Akebia Therapeutics Inc [NASDAQ:AKBA] saw its stock jump 6.19% to $2.40. Over the last five days, the stock has gained 29.03%. Akebia Therapeutics Inc shares have risen nearly 26.32% since the year began. Nevertheless, the stocks have risen 70.21% over the past one year. While a 52-week high of $2.48 was reached on 01/27/25, a 52-week low of $0.80 was recorded on 03/13/25. SMA at 50 days reached $2.02, while 200 days put it at $1.60.
Levels Of Support And Resistance For AKBA Stock
The 24-hour chart illustrates a support level at 2.25, which if violated will result in even more drops to 2.11. On the upside, there is a resistance level at 2.47. A further resistance level may holdings at 2.55. The Relative Strength Index (RSI) on the 14-day chart is 67.06, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 0.00%. Stochastics %K at 77.19% indicates the stock is a holding.
How much short interest is there in Akebia Therapeutics Inc?
A steep rise in short interest was recorded in Akebia Therapeutics Inc stocks on 2025-02-28, growing by 0.43 million shares to a total of 14.88 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 14.45 million shares. There was a rise of 2.86%, which implies that there is a positive sentiment for the stock.
